Nxera Pharma has received $10 million after a fourth R&D milestone was met in the company’s collaboration with AbbVie. Nxera and AbbVie entered a multi-target collaboration in 2022 to leverage Nxera’s NxWave platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease. The fourth… Read More
Nxera Pharma has received $10 million from pharmaceutical company AbbVie under the terms of the multi-target discovery collaboration on neurological diseases, Nxera has announced. Nxera and AbbVie entered the multi-target collaboration in 2022, leveraging Nxera’s NxWave platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated… Read More
Biopharmaceutical company Nxera Pharma has launched a broad new pipeline strategically focused on advancing therapies for obesity and associated metabolic disorders. Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline… Read More
A new multi-target partnership aims meet unmet need by designing antibodies for G-protein coupled receptors (GPCRs). The collaboration will combine Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries’, with Nxera’s NxWave platform for GPCR target selection, validation and structural determination. Read More
Nxera Pharma Japan has received approval from the Ministry of Health, Labour and Welfare of Japan (MHLW) of its New Drug Application (NDA) for ACT-541468 (daridorexant or Quviviq) in 25 and 50mg doses for the treatment of adult patients with insomnia. The approval of Quviviq, a… Read More
